Kowa
As of the edition of 20 October 2026, Kowa runs 10 drugs, 7 of them marketed; it is on route A at 0 targets and on route B at 3 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 7 |
| Went quiet | 2 |
| Stopped | 1 |
| Total | 10 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Ezetimibe | none listed | 3 |
| Valproic acid | none listed | 2 |
| Pitavastatin | none listed | 1 |
| Ripasudil | none listed | 0 |
| Tofogliflozin anhydrous | none listed | 1 |
| Anagliptin | none listed | 1 |
| Pemafibrate | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 3 targets.
All 3 rows on route A or B
In the product3 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 3 targets where Kowa needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nutrition and metabolism: 6 trials led
- Digestive system: 1 trials led
- Hormones: 1 trials led